Related Experiment Video
Updated: Dec 31, 2025
07:15
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
10.2K
Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition
Yangyang Liu1, Chaorui Wang1, Jinshan Li1
1State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, P.R. China.
Summary
Phellinus linteus polysaccharide extract (PLPE) regulates gut microbiota to increase beneficial short-chain fatty acids (SCFAs). This improves gut barrier function, reduces inflammation, and reverses insulin resistance in type 2 diabetic rats.
Area of Science:
- Microbiology
- Pharmacology
- Metabolic Diseases
Background:
- Phellinus linteus polysaccharide extract (PLPE) shows hypoglycemic effects, but its interaction with gut microbiota and insulin resistance is unclear.
- Understanding the gut microbiota's role is crucial for managing type 2 diabetes.
- Investigating PLPE's mechanism can reveal novel therapeutic strategies.
Purpose of the Study:
- To investigate the regulatory effect of PLPE on gut microbiota composition.
- To elucidate the molecular mechanism by which PLPE improves insulin resistance.
- To assess PLPE's potential as a prebiotic in a type 2 diabetic rat model.
Main Methods:
- A type 2 diabetic rat model was established and treated with saline, metformin, or PLPE for 8 weeks.
- Gut microbiota composition was analyzed, focusing on short-chain fatty acid (SCFA)-producing bacteria.
- Intestinal barrier function, blood lipopolysaccharides, and insulin resistance markers were assessed.
Main Results:
- PLPE significantly increased the abundance of SCFA-producing bacteria.
- Elevated SCFA levels were observed, correlating with improved intestinal barrier integrity.
- PLPE treatment reduced blood lipopolysaccharides and systemic inflammation, leading to reversed insulin resistance.
Conclusions:
- PLPE, rich in polysaccharides, modulates gut microbiota to enhance SCFA production.
- This mechanism improves intestinal barrier function and reduces inflammation, thereby ameliorating insulin resistance.
- PLPE demonstrates potential as a prebiotic for managing type 2 diabetes by regulating gut microbiota.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
514
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
514
01:24Glucagon-like Receptor Agonists
780
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
780
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
480
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
480
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
539
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
539
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.0K
01:28Insulin: The Receptor and Signaling Pathways
2.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.5K